Hammernews bei Human Biosystems ! - 500 Beiträge pro Seite

[Graffy]

Die News kam Gestern nachbörslich:

Breaking News: Human BioSystems Signs Letter of Intent to Acquire Ethanol Projects
Thursday July 27, 4:05 pm ET

PALO ALTO, CALIFORNIA--(MARKET WIRE)--Jul 27, 2006 -- Human BioSystems ("HBS") (OTC BB:HBSC.OB - News), a developer of preservation platforms for organs and other biomaterials, announced today that it has signed a letter of intent ("LOI") to acquire two ethanol production facility projects from EXL III Group Corporation ("EXL III"), an equity partner in ethanol plant ventures. HBS will also enlist the services of Claude Luster III, the principal of EXL III Group Corporation, to serve as the President of a new subsidiary to be formed to develop the ethanol business.

The LOI provides that HBS will acquire the projects from EXL III Group Corporation for restricted HBS common stock. In addition, HBS will enter into a Consulting Services Agreement with Mr. Luster.

"We made the decision to enter the bio energy field because it gives HBS the potential to achieve substantial revenue and profit growth within a predictable timetable, and because the opportunity and expertise to pursue the renewable energy market exists with this acquisition," stated Harry Masuda, CEO of Human BioSystems. "This acquisition should give HBS additional financing options not previously available," continued Mr. Masuda.

The acquisition, which is expected to close in the fall of 2006, is subject to certain conditions, including but not limited to completion of satisfactory due diligence by HBS, the negotiation and completion of a definitive acquisition agreement and Consulting Services Agreement, approval of the HBS and EXL III boards of directors and other customary conditions.

HBS is headquartered in Palo Alto, California with research facilities in Michigan.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, failure to complete a final definitive agreement, failure to obtain regulatory approvals for the construction of ethanol plants, failure to obtain the required financing and to construct the ethanol plants, failure of the ethanol plants to meet standards, the inability to find raw material for the production of ethanol or to sell the ethanol at on acceptable terms, the risks involved in pursuing a business unrelated to HBS' prior business, and other factors discussed in filings made by the Company with the Securities and Exchange Commission



Contact:
Contacts:
Human BioSystems
Harry Masuda
[phone]

Yes International
Investor Relations
[phone]

Concept Communications Group LLC
Investor Relations
[phone]



--------------------------------------------------------------------------------
Source: Human BioSystems

[Graffy]

[Okawanga]

Antwort auf Beitrag Nr.: 23.150.708 von Graffy am 28.07.06 14:40:35

Was soll das denn geben?

Machen die jetzt in Erneuerbare Energien oder was? kein Geld
für Aktienrückkäufe und dann so was, sei mir nicht böse aber
das ist Kappes.


Gruss Oka

[Graffy]

Antwort auf Beitrag Nr.: 23.150.836 von Okawanga am 28.07.06 14:50:25

Was bringt mehr: Aktienrückkauf ohne Ethanol mit selben aussichten oder Ethanol mit Umsatz und Gewinnsteigerung?

Was soll daran Kappes sein?

[Montypower]

Da kommt was ganz großes auf uns zu !!
ich sehe Kurse von mind. 1 € und mehr

[Graffy]

Wall Street News Alert: HBSC Is Friday's Stock to Watch! July 28, 2006
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.
Jul 28, 2006 8:38:00 AM
WESTON, FL -- (MARKET WIRE) -- 07/28/06 -- Wall Street News Alert's "stocks to watch" this morning are: Human Biosystems (OTCBB: HBSC), Pfizer Inc. (NYSE: PFE), Applied Materials, Inc. (NASDAQ: AMAT) and Amazon.com (NASDAQ: AMZN).

Human Biosystems (OTCBB: HBSC) may be a target of aggressive investors and day traders this morning! Yesterday after the stock markets closed, the company, a developer of preservation platforms for organs and other biomaterials, issued a press release announcing that it has signed a letter of intent ("LOI") to acquire two ethanol production facility projects from EXL III Group Corporation, an equity partner in ethanol plant ventures.

News of the letter of intent may be of interest to investors! "We made the decision to enter the bio energy field because it gives HBS the potential to achieve substantial revenue and profit growth within a predictable timetable, and because the opportunity and expertise to pursue the renewable energy market exists with this acquisition," stated Harry Masuda, CEO of Human BioSystems. "This acquisition should give HBS additional financing options not previously available," continued Mr. Masuda.

Wall Street News Alert is placing Aggressive Investors on alert to monitor the progress of Human Biosystems! The acquisition, which is expected to close in the fall of 2006, is subject to certain conditions, including but not limited to completion of satisfactory due diligence by HBS, the negotiation and completion of a definitive acquisition agreement and Consulting Services Agreement, approval of the HBS and EXL III boards of directors and other customary conditions. According to the press release, the LOI provides that HBS will acquire the projects from EXL III Group Corporation for restricted HBS common stock.

HBS will also enlist the services of Claude Luster III, the principal of EXL III Group Corporation, to serve as the President of a new subsidiary to be formed to develop the ethanol business.

Prior to the latest press release, the stock closed yesterday at around Nineteen cents a share.

For an in-depth profile of Human Biosystems, visit http://www.thenewssvc.com/HBSC072706.html.

To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit www.WallStreetNewsAlert.com, where you may also sign up to receive free email alerts in advance of our press releases being issued.

Pfizer Inc (NYSE: PFE) up 2.1% on 35.9 million shares traded. Pfizer is a pharmaceutical company.

Applied Materials, Inc. (NASDAQ: AMAT) up 0.3% on 29.6 million shares traded. Applied Materials, Inc. is the global leader in nano-manufacturing technology.

Amazon.com (NASDAQ: AMZN) up 1.1% on 26.3 million shares traded.

Commentary:

"Oil profits are big, big, big once again. ExxonMobil, the world's largest publically traded company, said second quarter profits were at $10.36 billion or up by 36%; that's a mere $323 million above economists forecast. No slouch Royal Dutch Shell also came in with a big number, $7 billion in profits for the quarter. Also, ConocoPhillips, the third largest U.S. oil company, had record $5.19 net income, a 65% gain above last year," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at: http://www.WallStreetNewsAlert.com.

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at [e-mail].

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 50 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at http://www.wallstreetnewsalert.com and select the "join now" button.

WSNA is a Platinum Sponsor of Quality Stocks. Quality Stocks tracks the stock picks of 150 Investment Newsletters every day and reports on their performance. For Their Free Service, Visit www.qualitystocks.net.

*** It has come to the attention of Wall Street News Alert (WSNA), that various persons or companies distribute faxes bearing similar names to Wall Street News Alert. Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street.***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. (WSCF has been compensated Ten Thousand Dollars for current coverage AND was previously compensated Twenty Eight Thousand Dollars for past coverage of Human Biosystems (OTCBB: HBSC), by the company, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact email: Email Contact
URL: http://www.wallstreetnewsalert.com
Company: Wall Street News Alert

[Graffy]

[Graffy]

RT 0,21$

[Graffy]

Kurs schon bei 0,22$

[zizzi]

Antwort auf Beitrag Nr.: 23.151.518 von Graffy am 28.07.06 15:34:04

süpi, bin wieder mal "blind" in einen hype rein... klaaaasse !!

jetzt SL setzen und genüsslich zuschauen. wohin geht die reise noch ?

[Graffy]

Antwort auf Beitrag Nr.: 23.151.563 von zizzi am 28.07.06 15:36:17

Bestimmt bis 0,50$ Anfang nächster Woche

[Montypower]

eher bei 1,00 $$$$$

[int00]

so,so
ich spring hier auch mal rein, mal sehen wo es hingeht

[zizzi]

Antwort auf Beitrag Nr.: 23.151.702 von Montypower am 28.07.06 15:41:58

na, na, nicht so schnell...

kommt wieder etwas zurück. ich bleibe nicht zu lange drin. das zockerpapier ist mir zu heiss. sollte nicht wieder unter 0.2 fallen

[cyber2k]

Last:

0.21 HBSC - HUMAN BIOSYSTEMS
Change:

+0.02 % Change:

+10.53% High:

0.22 Low:

0.19 Volume:

512,804

[Graffy]

Zu 0,21$ wird kräftig eingekauft, die halten nicht mehr lange

[int00]

wir knacken gleich das gestrige Volumen

[int00]

die muss heute die 0,225 packen.

[Graffy]

Market News First (mn1.com) to Interview Harry Masuda, CEO of Human BioSystems on HBSC's Breaking News

Human BioSystems (OTCBB:HBSC), announced today that Harry Masuda, CEO, will be interviewed by Market News First Radio (www.mn1.com), Friday (28 July 2006) at 10:00 am EDT.

In this exclusive interview, Mr. Masuda will brief the listening audience on the Letter of Intent that Human BioSystems just signed to acquire two ethanol production facility projects from EXL III Group Corporation ("EXL III"), an equity partner in ethanol plant ventures.

At the close of the market on Thursday, July 27, 2006, Mr. Masuda, CEO of Human BioSystems, stated in a news release, "We made the decision to enter the bio energy field because it gives HBS the potential to achieve substantial revenue and profit growth within a predictable timetable, and because the opportunity and expertise to pursue the renewable energy market exists with this acquisition. This acquisition should give HBS additional financing options not previously available," continued Mr. Masuda.

HumanBioSystems, a developer of preservation platforms for organs and other biomaterials, specializing in the development of proprietary above zero ("HBS-AZ") and below zero ("HBS-BZ") organ and tissue preservation systems and methods for preserving blood platelets, has made tremendous advancements in their research and testing of their proprietary preservation methods over the past year and is now beginning the process to prepare their application to the FDA to obtain a license to begin performing human testing.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for human studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, issues with the patentability and/or protection of the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.


Human BioSystems
Harry Masuda, 650-323-0943
[e-mail]
or
Investor Relations:
Concept Communications Group
James Caldwell, 727-447-0514
[e-mail]
or
YES INTERNATIONAL
Rich Kaiser, 800-631-8127
[e-mail]



Source: Business Wire (July 28, 2006 - 9:40 AM EDT)

[zizzi]

Antwort auf Beitrag Nr.: 23.152.884 von Graffy am 28.07.06 16:45:27

und für einen wenig-englisch-sprechenden bedeutet ??

[mfierke]

wenn sie nur nicht wieder absackt

[bioperformer]

Antwort auf Beitrag Nr.: 23.150.836 von Okawanga am 28.07.06 14:50:25

...wart nur mal wenn die dann erst mal in Erdölgeschäft einsteigen und nach Gold buddeln...

...kopfschüttel....

[zizzi]

Antwort auf Beitrag Nr.: 23.153.133 von bioperformer am 28.07.06 17:02:11

aah schau an, unser lieber bio.

man macht nicht jeden tag 50 %, darum kannst du dir das bashen hier wenigstens sparen (obwohl du ja auch schon recht hattest )

[cyber2k]

kleine pause am Freitag...heute gehts wieder uppp

[Montypower]

Human BioSystems Invites Interested Parties, Shareholders and Listeners to Hear HBSC's CEO Speak on Ethanol


2006-08-24 11:34 ET - News Release

PALO ALTO, Calif. -- (Business Wire) -- Aug. 24, 2006
Company Website: http://www.humanbiosystems.com

Human BioSystems (OTCBB:HBSC), announced today that
Harry Masuda, CEO, will be discussing the topic of ethanol production
on a variety of radio stations and invites listeners, interested
parties, and shareholders in those areas to tune in to receive
important information on the company's planned expansion into the
production of biofuels, specifically ethanol.
-0-
*T

His scheduled appearances are detailed as follows:

Thursday, August 24, 2006
KFYR AM 550 Radio - North Dakota
3:10 CST

Friday, August 25, 2006
KZIM News Radio 960 AM, Missouri
12:30 am CST

Monday, August 28, 2006
WKEB 99.3 FM Radio & WIGM 1490 AM Radio - Medford, Wisconsin,
10:15 am CST

Wednesday, August 30, 2006
KFOR 1240 AM Radio - Lincoln, Nebraska
10:00 am CST

Thursday, August 31, 2006
KXYL FM 96.9
5:15 pm CST

Tuesday, September 5, 2006
KFWB News 980 AM Radio, Los Angeles, CA
Online: http://www.kfwb.com
9:00 am PST

Wednesday, September 6, 2006
Market News First Radio, Texas
Online: http://www.mn1.com
2:00 pm CST

*T

Human BioSystems, the developer of preservation platforms for
organs and platelets, recently signed a letter of intent to enter into
the BioFuels business through the acquisition of two ethanol
production facility projects. The Palo Alto based Company, has made
significant progress in its nine-year history to maximize its zone
of responsibility for the health and welfare of the people and their
environments.

Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because such statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that
could cause results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to, results from ongoing research and development as well as
clinical studies, failure to obtain regulatory approval for the
Company's products, if required, failure to develop a product based on
the Company's technology, failure of any such products to compete
effectively with existing products, the inability to find a strategic
partner or to consummate a relationship with a potential strategic
partner on acceptable terms, and other factors discussed in filings
made by the Company with the Securities and Exchange Commission.
Contacts:

For Human BioSystems, Palo Alto
Concept Communications
James Caldwell, 727-447-0514
[e-mail]

[Montypower]

Press Release Source: Human BioSystems


Human BioSystems CEO, Harry Masuda to Appear on Market News Radio (www.mn1.com) Wednesday, Sept. 6, 2006
Tuesday September 5, 3:32 pm ET


PALO ALTO, Calif.--(BUSINESS WIRE)--Sept. 5, 2006--Human BioSystems (OTCBB:HBSC - News), announced today that Harry Masuda, CEO, will appear on Market News Radio, Wednesday, September 06, 2006 at 3:00 pm EDT to discuss the company's recent breaking news on the formation of HBS BioEnergy ("HBE") which will operate as a separate company and subsidiary of HBS for the purpose of developing the bio energy business including the two ethanol fuel production facility projects to be acquired from EXL III Group Corporation ("EXL III") pursuant to the Letter of Intent ("LOI") mentioned in the press release dated July 27, 2006.
Mr. Masuda will also be appearing on the following stations this week to update shareholders, listeners, and interested parties, on the formation of HBS BioEnergy.

His scheduled appearances for the week are detailed as follows:

Tuesday, September 5th, 2006
KFWB News 980 Radio - Los Angeles, CA
http://www.kfwb.com
12:00 noon EDT

Wednesday, September 6th, 2006
Market News First - Houston, TX
http://www.mn1.com
3:00 pm EDT

Thursday, September 7th, 2006
TalkStar Radio - Northern & Central Florida
http://www.talkstarradio.com
3:00 pm EDT

[crackerjack]

ACHTUNG!!!! HBS WIRD EXPLODIEREN!!!! NEWS!!!

Human BioSystems Scheduled to Meet with the FDA to Discuss Platelet Human Infusion Testing
Tuesday September 12, 4:05 pm ET

PALO ALTO, Calif.--(BUSINESS WIRE)--Sept. 12, 2006--Human BioSystems ("HBS" or "Company") (OTCBB:HBSC - News) announced today that a pre-IND (Investigational New Drug) application meeting with the FDA (Food and Drug Administration) has been scheduled for early October to discuss HBS's plan to conduct human infusion tests using the Company's patented platelet preservation system.

ADVERTISEMENT

The Pre-IND meeting is a prelude to a formal application and request to proceed with human testing once all concerns and requirements of the FDA are satisfied. The planned studies will involve a number of human subjects that are infused with platelets stored in the cold using the HBS process and compared to platelets prepared using the current storage method. The platelets are uniquely labeled prior to infusion to distinguish the HBS platelets from the control group, and monitored for platelet survival in the bloodstream over time.

Dr. David Lucas, Director of Platelet Development for HBS stated that "Studies have shown that standard blood platelets stored in the cold for 24 hours or longer are not functional and are quickly eliminated from the blood after infusion. It is our goal to show that HBS platelets will maintain functionality and continue to circulate in the bloodstream for more than a few hours and ideally even for days after infusion. The HBS platelets will be stored at refrigerated temperatures for several days prior to infusion."

The advantages of the HBS cold stored platelets are potentially longer shelf life, fresher and higher quality platelets, cost savings due to fewer platelet transfusions and significant savings of expenses due to the reduction of outdates compared to platelets stored under current methods.

Dr. David Winter, President of HBS confirmed that "The basis for proceeding to human infusion studies is the result of positive in-vitro test data obtained at two independent research centers in the United States. This Pre-IND meeting is a positive step toward our goal to demonstrate that cold stored platelets using HBS technology can maintain functionality after storage for more than 24 hours, which to our knowledge, has never been demonstrated before."

Blood platelets are the congealing component in blood, and are an essential part of the treatment for cancer patients who have undergone chemotherapy. Current regulations provide for the storage of platelets at room temperature for 5 days.

Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made significant progress in its nine-year history. This scheduled meeting is another milestone for Human BioSystems in achieving its goal to commercialize its technologies.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission

[SteveKing]

Hier eine freie Übersetzung dieser News:

Human BioSystems plant ein Treffen mit der FDA um Menschliche Blutplättchen Infusionen mit ihrem patentierten System durchführen zu dürfen. Dieses Meeting wird Anfang Oktober anberaumt.

Sinn diese Meetings ist ein formeller Antrag nach den In-vitro Tests nun Test an Menschen durchführen zu dürfen sofern alle Anforderungen seitens der FDA erfüllt sind. Geplant sind dabei Test an mehreren Personen mit der neuen HBS Technologie verglichen zur herkömmlichen Methode. Die indizierten HBS Blutplättchen werden dabei speziell gekennzeichnet um ihr Überleben im Blut beobachten zu können.

Dr. David Lucas sagt dazu, dass bisherigen Studien belegen, dass standardmäßig 24 Stunden oder länger gekühlte Blutplättchen nicht mehr funktionsfähig sind und rasch nach der Infusion vom Blut ausgeschieden werden. Er will aufzeigen, dass HBS gekühlte Blutplättchen ihre Funktionalität behalten und im Blut für einige Stunden, idealerweise sogar Tage nach der Infusion noch zirkulieren.

Vorteile der HBS Kühltechnologie sind möglicherweise längere Lagerfähigkeit , frischere und höhere Qualität der Blutplättchen, Kostenersparnis auf Grund von weniger Transfusionen und signifikante Einsparungen der Kosten durch Verringerung des Ausschusses verglichen mit bisherigen Methoden.

…

Dieses geplante Meeting ist ein weiterer Meilenstein in der Geschichte von Human BioSystems in der Erreichung ihres Zieles diese Technologie zu kommerzialisieren!

Übersetzung: Stefan K. alias SteveKing

[Montypower]

und schon wieder SUPER-NEWS

HBS BioEnergy Appoints Mr. Claude Luster as President for its Renewable Energy Business
Monday October 9, 4:05 pm ET


PALO ALTO, Calif.--(BUSINESS WIRE)--Human BioSystems (OTCBB:HBSC - News; "HBS") announced today that HBS BioEnergy ("HBS Bio"), a wholly owned subsidiary of HBS, has appointed Mr. Claude Luster III as HBS BioEnergy's President, pursuant to the agreement signed between HBS and HBS Bio in September, 2006. Mr. Luster, the founder of EXL III Group Corporation (EXL III), has been involved in the final stages of developing and funding a 60-million gallon Northern California ethanol facility which he will complete while assuming his new duties with HBS BioEnergy.
ADVERTISEMENT


"Among Mr. Luster's first duties will be to develop necessary strategic partners and consulting firms that HBS BioEnergy will need for the initial stages of production," stated Harry Masuda, CEO of Human BioSystems. "We are pleased to have Claude as our President. He has the technical and management background and the essential skills that HBS has been seeking," Mr. Masuda continued.

Mr. Luster was instrumental with EXL III's current plans to develop up to 10 renewable fuels plants and 10 value added bioconversion facilities. EXL III is also developing several new cost reduction processes for the production of ethanol and biodiesel.

Prior to his involvement with the EXL III, Mr. Luster was President and CEO of EXL Group, a Portfolio Investment Company of Impact Capital Partners of Oakland, CA which includes Wells Fargo and, Washington Mutual as Limited Partners.

Mr. Luster has more than 30 years experience in the food-processing, bio-conversion, energy and environmental industries and is considered one of the food industry's leading experts in the field of aseptic processing and aseptic bulk plant operations. These involve highly complex processes utilizing sophisticated equipment and manufacturing procedures. Ethanol production utilizes processes and equipment that bear close resemblance to those of the food processing industry.

Included amongst Mr. Luster's credentials are the conception, development and implementation of novel aseptic processes and protocols directed towards developing Greenfield food processing and bio-conversion facilities in the United States, Canada, China and Africa. He owned and operated LusTek Labs and Consulting as well as serving as consultant in the food processing, bio-conversion, energy and environmental industries. He was a major shareholder in Helm Concentrates, Inc., which was subsequently sold to ConAgra Foods, Inc.

Mr. Luster has held numerous technical, scientific and management positions including Process Technician for General Foods, Inc., Process Operations and Research Manager for Tri-Valley Growers, Fermentation Manager for Miller Brewing Company, Vice President of Operations for Helm Concentrates, Inc. and Technical Leader for Hunt-Wesson Foods, Inc. While at Helm Concentrates Inc, Mr. Luster designed and supervised the construction of one of the most sophisticated aseptic processing plants in California.

"I see HBS Bio as an innovative company, prepared to join the burgeoning group of professionals who keep abreast of the ever-shifting trends in energy and environmental markets and who are constantly working to provide optimal solutions for the consumer. I'm pleased to be appointed to the position of President and look forward to a strong future with HBS Bio," stated Claude Luster III, President of HBS BioEnergy.

In September of 2006, HBS created HBS BioEnergy, a wholly owned subsidiary dedicated to the development facilities that produce ethanol and other biofuels.

Human BioSystems is a developer of preservation platforms for organs and other bio-materials. HBS is headquartered in Palo Alto, California with research facilities in Michigan and has been granted four patents by the U.S. Patent Office.

Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, failure to obtain regulatory approvals for the construction of ethanol plants, failure to obtain the required financing and to construct the ethanol plants, failure of the ethanol plants to meet standards, the inability to find raw material for the production of ethanol or to sell the ethanol at acceptable terms, the risks involved in pursuing a business unrelated to HBS' prior business, and other factors discussed in filings made by the Company with the Securities and Exchange Commission

[SteveKing]

Was auf Deutsch so viel heißt wie:

HBS BioEnergy ernennt Mr. Claude Luster zum Präsidenten für ihre erneuerbare Energie Sparte

Paolo Alto, CA – 9. Oktober 2006 – (OTCBB:HBSC) – Human BioSystems (“HBS”) gibt heute bekannt, dass gemäß der getroffenen Vereinbahrung zwischen HBS und HBS BioEnergiy („HBS Bio“) Mr. Claude Luster als Präsident für HBS Bio ernannt wurde.
Mr. Luster, der Gründer der EXL III Group Corporation (EXL III) war involviert im Endstadium der Entwicklung und Förderung einer 60 Millionen Gallionen Northern California Ethanol Anlage. Diese wird er fertigstellen während er die neuen Agenten für HBS BioEnergy übernimmt.

....

Im weiteren Text der Presseaussendung steht mehr oder weniger die gesamte Lebensgeschichte von Mr. Claude Luster. Diese könnte ihr dann am Donnerstag um 10:00 Uhr aus der offiziellen Übersetzung entnehmen!!

Have a nice day!
Steve

[Montypower]

Form 8-K for HUMAN BIOSYSTEMS INC


--------------------------------------------------------------------------------

13-Oct-2006

Completion of Acquisition or Disposition of Assets, Creation of a Direct Fin



Item 2.01 Completion of Acquisition or Disposition of Assets.
On October 6, 2006, Human BioSystems ("HBS") a California corporation, HBS BioEntergy ("HBS Bio"), a California corporation and a wholly-owned subsidiary of HBS, and Excel III Group Corporation ("EXL") completed the transactions contemplated by the Asset Purchase Agreement, Consulting Services Agreement, and Escrow Agreement entered into between the parties on September 25, 2006, and effective September 1, 2006.

Pursuant to the Asset Purchase Agreement, EXL agreed to sell options to purchase certain property in Lumberton County, North Carolina, to HBS Bio. In consideration for the options, HBS Bio issued 50,000 shares of HBS common stock to EXL and reimbursed EXL $40,000 for expenses incurred with respect to the options and related proposed ethanol projects, discussed further below.

The Consulting Services Agreement provides that EXL will supervise, manage, and coordinate the development, construction, and operation of up to three ethanol facilities. The Consulting Services Agreement also provides that EXL's President, Claude Luster, III, will have the title of President of HBS Bio during the term of the Consulting Services Agreement, and will report to HBS Bio's Chief Executive Officer. The term of the Consulting Services Agreement is two years from the effective date, with an option to extend the term for two additional years by mutual written agreement.

In consideration for its consulting services, EXL will receive an annual consulting fee of $199,000. Upon the funding of the first ethanol facility, the annual consulting fee will increase to $224,000. The consulting fee will increase again to $324,000 upon the funding of the second ethanol facility, and to $424,000 in the even a third ethanol facility is funded.

The Consulting Services Agreement also provides that the facilities will be funded by HBS according to a schedule, with $300,000 due upon closing of the Asset Purchase Agreement and additional amounts upon completion of certain milestones thereafter. HBS will contribute $150,000 upon completing the following milestones: (1) raw product supply agreement for the first plant; (2) environmental services agreement for the first plant; (3) risk management agreement for the first plant; and (4) distilled grain marketing agreement for the first plant. HBS will contribute an additional $150,000 upon completing the following milestones: (1) ethanol off take agreement for the first plant; (2) preliminary engineering study for the first plant; (3) land use permit submittal for the first plant; (4) environmental permits submittal for the first plant;
(5) financial advisory services agreement or letter of interest from financial entity; (6) land option agreement for the second plant; and (7) fuel supply agreement for the first plant. HBS will contribute $400,000 upon reaching the following milestones: (1) utility services agreement for the first plant; (2) Phase I engineering and environmental for the first plant; (3) raw product supply agreement for the second plant; (4) environmental services agreement for the second plant; (5) risk management agreement for the second plant; and (6) distilled grain marketing agreement for the second plant. HBS will contribute $450,000 upon reaching the following milestones: (1) EPC Agreement and Phase II engineering for the first plant; (2) fuel supply agreement for the second plant;
(3) utility services agreement for the second plant; (4) ethanol off take agreement for the second plant; (5) environmental permits submittal for the second plant; (6) preliminary engineering study for the second plant; (7) land use permit submittal for the second plant; (8) Phase I engineering and environmental studies for the second plant; (9) long term equity commitment for first plant (10) long term debt commitment for the first plant; (11) issuance of authority to construct permits for the first plant; and (12) final funding documentation for the first plant. Finally, HBS will contribute $400,000 upon completing the following milestones: (1) EPC Agreement and Phase II engineering for the second plant; (2) long term equity commitment for the second plant; (3) long term debt commitment for the second plant; (4) final environmental permits for the second plant; (5) authority to construct permits for the second plant; and (6) final funding documentation for the second plant.


-1-
EXL will also be entitled to receive up to 3,450,000 shares of HBS common stock.
The stock will be placed in escrow, and to that end, HBS Bio, EXL, and Silicon Valley Law Group as escrow agent entered into an Escrow Agreement. The Escrow Agreement provides that 1,000,000 shares of HBS common stock will be released to EXL upon the execution of certain agreements necessary for the development of the first ethanol facility, the submission of preliminary environmental and land use permits for the first ethanol facility, and the assignment and conveyance of the option to purchase the second facility. An additional 1,000,000 shares will be released to EXL upon the acquisition of certain permits for the first facility and the execution of certain agreements necessary for development of the first facility, as well as the submission of preliminary environmental and land use permits for the second facility. The 1,450,000 remaining shares will be released to EXL when a funding commitment for the first facility is obtained.
In the event funding for the first facility is not obtained within four months from the date on which the funding commitment is received, any shares still in escrow will be dispersed to HBS Bio and any shares previously released to EXL will be returned to HBS Bio.





Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
As stated above in Item 2.01, which is expressly incorporated herein by reference, the Asset Purchase Agreement obligates HBS Bio to issue 50,000 shares of HBS common stock to EXL and reimburse EXL $40,000 for expenses incurred with respect to the options and related proposed ethanol projects.

The Consulting Services Agreement requires HBS to pay EXL an annual consulting fee of $199,000, which will be increased to $224,000 upon the funding of the first ethanol facility, $324,000 upon the funding of the second ethanol facility, and $424,000 in the event a third facility is funded. EXL will also be entitled to 3,450,000 shares of HBS common stock, no par value per share, to be released to EXL pursuant to the Escrow Agreement as described in Item 2.01 above.

HBS will also be required to fund the proposed ethanol facilities according to the schedule provided by the Consulting Services Agreement and as described in Item 2.01 above.





Item 3.02 Unregistered Sales of Equity Securities.
As stated above in Item 2.01, which is expressly incorporated herein by reference, under the Consulting Services Agreement, HBS was obligated to issue 3,450,000 shares of common stock. The issuance was made in reliance on Section 4(2) of the Securities Act of 1933, as amended and was made without general solicitation or advertising. The recipient was a sophisticated investor with access to all relevant information necessary to evaluate the investments, who represented to HBS and HBS Bio that the shares were being acquired for investment purposes.





Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Pursuant to the Consulting Services Agreement, as described in Item 2.01 and herein incorporated by reference, Claude Luster III was appointed as President of HBS Bio effective September 1, 2006. Mr. Luster is the founder of EXL, and has been involved in the final stages of developing and funding a 60-million gallon ethanol facility in Northern California.


-2-
Prior to his involvement with EXL, Mr. Luster was President and CEO of EXL Group, a Portfolio Investment Company of Impact Capital Partners of Oakland, CA.
Mr. Luster has more than 30 years experience in the food-processing, bio-conversion, energy and environmental industries and is considered one of the food industry's leading experts in the field of aseptic processing and aseptic bulk plant operations. Mr. Luster conceived, developed, and implemented novel processes and protocols directed towards developing Greenfield food processing and bio-conversion facilities in the United States, Canada, China, and Africa.
He owned and operated LusTek Labs and Consulting and served as a consultant in the food processing, bio-conversion, energy and environmental industries. Mr. Luster has held numerous technical, scientific and management positions including Process Technician for General Foods, Inc., Process Operations and Research Manager for Tri-Valley Growers, Fermentation Manager for Miller Brewing Company, Vice President of Operations for Helm Concentrates, Inc., and Technical Leader for Hunt Wesson Foods, Inc.

There are no transactions between Mr. Luster and the Company that would require disclosure under Item 404(a) of Regulation S-B. Mr. Luster is not currently serving on any committee of the Board of Directors.

Exhibit No. Description